Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Aidite Qinhuangdao Technology Co Ltd (301580.SZ)
Qinhuangdao, CN
Aidite (Qinhuangdao) Technology Co., Ltd. is a key player in the research, development, production, and commercialization of advanced zirconia materials for dental applications. The company offers a comprehensive suite of dental solutions under its 'Cameo' brand. This extensive portfolio encompasses cutting-edge materials like Cameo 3D instant restorative zirconia and Cameo glass ceramics, alongside essential equipment. These include the Cameo intraoral scanner, the Cameo N4 and AV-D5 milling machines (with specialized systems for dry zirconia milling via the AV-D5 and wet glass ceramics milling via the N4), as well as Cameo fast sintering and glaze furnaces, providing a complete workflow for dental professionals. Established on March 15, 2007, by co-founders Hong Wen Li and Bin Li, the enterprise is headquartered in Qinhuangdao, China.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -3.70% | -9.25% | -19.56% | -33.25% | +32.61% | +31.38% | +47.01% | -3.23% | -3.23% | -3.23% | -3.23% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-01 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 1 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Specialties: +8.3%+16.5% ★ Q1'26: +25.3% (vs Q1'25)
-
EPS growth Medical - Specialties: +10.1%+14.3% ★ Q1'26: +24.1% (vs Q1'25)
-
FCF margin FCF growth · Medical - Specialties: +51.3%+24.0% ★ Q1'26: -3.2% (vs Q1'25)
-
EBIT margin Medical - Specialties: +12.6%+20.9% ★ Q1'26: +17.6% (vs Q1'25)
-
ROIC Medical - Specialties: +6.6%+28.2% ★ Q1'26: +20.5% (vs Q1'25)
-
Share dilution Medical - Specialties: 0.0%+14.4% Q1'26: 0.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Specialties: -0.39×0.03× ★ Q1'26: 0.19× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|
| Revenue |
888.17M
est: 909.00M (-2.3%)
|
1.03B
est: 1.03B (+0.1%)
|
1.24B
1.24B – 1.24B
+20.1% YoY
|
1.51B
1.51B – 1.51B
+21.3% YoY
|
1.76B
1.76B – 1.76B
+17.1% YoY
|
| EBITDA |
198.34M
est: 195.73M (+1.3%)
|
257.19M
est: 222.60M (+15.5%)
|
267.32M
267.32M – 267.32M
+20.1% YoY
|
324.24M
324.24M – 324.24M
+21.3% YoY
|
379.71M
379.71M – 379.71M
+17.1% YoY
|
| EBIT |
174.12M
est: 175.42M (-0.7%)
|
216.65M
est: 199.50M (+8.6%)
|
239.58M
239.58M – 239.58M
+20.1% YoY
|
290.60M
290.60M – 290.60M
+21.3% YoY
|
340.31M
340.31M – 340.31M
+17.1% YoY
|
| Net Income |
150.49M
est: 163.77M (-8.1%)
|
196.22M
est: 195.15M (+0.5%)
|
258.07M
258.07M – 258.07M
+32.2% YoY
|
324.19M
324.19M – 324.19M
+25.6% YoY
|
431.90M
431.90M – 431.90M
+33.2% YoY
|
| SGA |
249.79M
est: 193.82M (+28.9%)
|
116.74M
est: 220.44M (-47.0%)
|
264.71M
264.71M – 264.71M
+20.1% YoY
|
321.09M
321.09M – 321.09M
+21.3% YoY
|
376.02M
376.02M – 376.02M
+17.1% YoY
|
| EPS |
1.61
est: 1.54 (+4.8%)
|
1.84
est: 1.83 (+0.5%)
|
2.42
2.42 – 2.42
+32.2% YoY
|
3.04
3.04 – 3.04
+25.6% YoY
|
4.05
4.05 – 4.05
+33.2% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-28 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-27 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-26 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-25 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-22 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-21 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-20 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-19 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-18 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-15 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-14 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-13 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-12 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-11 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-08 | B | 3/5 | 3/5 | 3/5 | 5/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-07 | B+ | 3/5 | 3/5 | 3/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-06 | B+ | 3/5 | 3/5 | 3/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-04-30 | B+ | 3/5 | 3/5 | 3/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-04-29 | B+ | 3/5 | 3/5 | 3/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-04-28 | B+ | 3/5 | 3/5 | 3/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-04-27 | B+ | 3/5 | 3/5 | 3/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-04-24 | B+ | 3/5 | 3/5 | 3/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-23 | B+ | 3/5 | 3/5 | 3/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-22 | B+ | 3/5 | 3/5 | 3/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-21 | B+ | 3/5 | 3/5 | 3/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-20 | B+ | 3/5 | 3/5 | 3/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-17 | B+ | 3/5 | 3/5 | 3/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-16 | B+ | 3/5 | 3/5 | 3/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-15 | B+ | 3/5 | 3/5 | 3/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-14 | B+ | 3/5 | 3/5 | 3/5 | 5/5 | 2/5 | 2/5 | 3/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Hongwen Li | Chairman of the Board & GM | — | male |
| Sheng Tang Zhang | Deputy GM & Director | — | male |
| Wan Dong Xie | Deputy General Manager | — | male |
| Xiangqian Kong | Chief Financial Officer | — | male |
| Yu Gao | Deputy GM & Board Secretary | — | female |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 301580.SZ
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
